Journal of Medicinal Chemistry · 2006 · 147 citations · 30 references
PharmacyMedicinal ChemistryOncologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLead DiscoveryStructure-activity Relationship AnalysisChemical Synthesis Of AnaloguesDose-dependent InductionLead Compound ScreeningLead ScaffoldsP53-dependent Apoptotic SignalingSmall-molecule Library SynthesisStructure-based Lead Discovery
From a set of weakly potent lead compounds, using in silico screening and small library synthesis, a series of 2-alkyl-3-aryl-3-alkoxyisoindolinones has been identified as inhibitors of the MDM2-p53 interaction. Two of the most potent compounds, 2-benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2,3-dihydroisoindol-1-one (76; IC(50) = 15.9 +/- 0.8 microM) and 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (79; IC(50) = 5.3 +/- 0.9 microM), induced p53-dependent gene transcription, in a dose-dependent manner, in the MDM2 amplified, SJSA human sarcoma cell line.
30
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Amplification of a gene encoding a p53-associated protein in human sarcomas
Jonathan D. Oliner, Kenneth W. Kinzler, Paul S. Meltzer et al. · Nature · 1992 · 2K citations · Full text
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Neil A. Bhowmick, Anna Chytil, David Plieth et al. · Science · 2004 · 1.4K citations